Biotech Laboratorios, C.A. company information, Employees & Contact Information

Roche's 'top three' obesity ambition not reliant on developing one megablockbuster Fierce Biotech

Introducing Fierce Medtech's Fierce 15 Fierce Biotech

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race Fierce Biotech

Nonprofit Cultivarium nets $10M to build tools for researchers studying fungi and archaea Fierce Biotech

Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail' Fierce Biotech

It's curtain close for Spotlight: Gene editing biotech shutters Fierce Biotech

Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win Fierce Biotech

Remote blood sample collector maker YourBio Health revamps leadership team Fierce Biotech

Fierce Biotech's Rotten Tomatoes of 2024 Fierce Biotech

'I don't feel we lost momentum': Takeda’s oncology execs sharpen focus after restructuring Fierce Biotech

Biotech faces a reckoning: 'We've lost our luster in cell therapies' Fierce Biotech

Amid the dip, biotech execs share silver linings in a tumultuous environment Fierce Biotech

The 2024 Biotech Graveyard Fierce Biotech

JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more Fierce Biotech

Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy Fierce Biotech

Fierce Biotech's 2021 Fierce 15 Fierce Biotech

Revolutionizing gene therapy logistics with Cryoport's Elite solution Fierce Biotech

Merck sets sights on brain cancer with $30M Modifi acquisition Fierce Biotech

JPM25: GSK's CSO shares science strategy behind dealmaking, plus plans to build off GLP-1s—but not for obesity Fierce Biotech

In conversation with Boston Scientific's global medical chief, Ken Stein, taking the pulse of pulsed field ablation Fierce Biotech

Takeda confirms fallout from gene therapy R&D refocus: up to 186 layoffs Fierce Biotech

FierceBiotech's 2019 Fierce 15 Fierce Biotech

After $213M round, gene editing biotech Tome shrinks operations as investor sentiment worsens Fierce Biotech

For biotech dealmakers, it’s everything, everywhere all at once Fierce Biotech

After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset Fierce Biotech

Frontier CEO weathers 'one of the hardest financings' of his career to close $80M series C Fierce Biotech

The future of accelerated approval for FDA's Marks? More rare disease drugs and no 'hanging chads' Fierce Biotech

Relay blames IRA for pause in plans to win approval in rare cancer, adding laps to its race to market Fierce Biotech

Cut to the core: Prescription app developer Pear Therapeutics files for bankruptcy, lays off staff Fierce Biotech

20 years in, Singapore still searches for its biotech success story Fierce Biotech

We have achieved peak biotech formation. It's time for 'musical chairs' Fierce Biotech

To get condensates into clinic next year, Dewpoint narrows headcount and pipeline Fierce Biotech

Flush with Wegovy cash, Novo Nordisk's owner widens investment strategy beyond biotech Fierce Biotech

Capsida reels in another Big Pharma deal, this time diving into eye disease with AbbVie Fierce Biotech

ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry Fierce Biotech

With Alnylam in rear view, Maraganore wants to be a biotech multiplier, matchmaker and mentor Fierce Biotech

Oruka spins out of Paragon with 3 assets, reverse merger and cash Fierce Biotech

Don't call it a comeback, but Neurona knocks out $120M raise a year after layoffs Fierce Biotech

Rough biotech market won't stop 5AM Ventures' new $750M life science funds Fierce Biotech

Sanofi moves patients out of Ukraine warzone in 'Herculean effort' to preserve MS trials Fierce Biotech

Late to the CAR-T game, AstraZeneca quietly works on its own off-the-shelf therapies Fierce Biotech

Aiming to disrupt the cardiovascular space, 2 industry vets unveil Boston biotech with preventive RNAi asset Fierce Biotech

Fierce Biotech's 2020 Fierce 15 Fierce Biotech

FierceBiotech's 2018 Fierce 15 Fierce Biotech

As Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market 'wide open' Fierce Biotech

Transatlantic Epidarex banks $126M to back U.K. biotech startups Fierce Biotech

Novo Nordisk's phase 3 data for hemophilia hopeful fail to shake off Pfizer's shadow Fierce Biotech

Remix Therapeutics debuts with $81M to 'reprogram' disease-causing RNA Fierce Biotech

Dyno grabs $100M to expand tech, build team, ink more gene therapy partnerships Fierce Biotech

LianBio nets $310M to bring medicines to Asia Fierce Biotech

Lexeo Therapeutics emerges with $85M, 18 gene therapy programs and a star-studded team Fierce Biotech

Women left out of VC club fight for their identity, pulling each other up one by one Fierce Biotech

BIO: Lightning round with John Maraganore Fierce Biotech

Frontier Medicines launches with $67M and biotech veteran Varma as CEO Fierce Biotech

Bitterroot emerges from undergrowth with $145M series A to grow fresh approaches to heart disease Fierce Biotech

LifeMine locks down $70M 'dream scenario' fungi partnership with GSK—and a fundraising, too Fierce Biotech

ADA: Dexcom plots 2024 launch of sensor for people with Type 2 diabetes who don't use insulin Fierce Biotech

The Power to Pivot: Using Dedicated Onsite Resources to Adapt Recruitment Practices in a Shifting Landscape Fierce Biotech

As Amgen zeroes in on cancer, neuroscience pipeline under the ax Fierce Biotech

FierceBiotech's 2017 Fierce 15 Fierce Biotech

Flip the Funnel: Rethinking Patient Recruitment and Enrollment Strategies Fierce Biotech

Neon CBO Robert Ang jumps ship to take the helm at Vor Biopharma Fierce Biotech

Eli Lilly cuts 3 cancer drugs amid Q4 clear-out Fierce Biotech

COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread Fierce Biotech

Biopharma vet Martin Williams takes the helm at autophagy biotech Caraway Therapeutics Fierce Biotech

Ex-GSK immunology chief takes over oncolytic virus biotech Candel as it ramps up its pipeline Fierce Biotech

Sarepta CEO Ed Kaye on FDA courage, NICE and resilience Fierce Biotech

AI drug prospector Atomwise to screen 10B compounds for potential childhood cancer therapies Fierce Biotech

In conversation with Tony Johnson, CEO of Goldfinch Bio Fierce Biotech

Genentech lays $310M wager on BioNTech’s mRNA cancer vaccine platform Fierce Biotech

Novartis taps growing Biofourmis for digital heart failure project Fierce Biotech

Little Milo wrestles for gene therapy spotlight Fierce Biotech

Why can’t some people stop eating? The hungry brain may be to blame Fierce Biotech